Oncopeptides (Q1 Initial take): Return to +30% Q/Q Growth in this Quarter - Redeye

Redeye provides its first take on Oncopeptides' Q1 report 2026. Sales grew 37% versus Q4 2025. Operating costs amounted to SEK-71m, with an EBIT of SEK-46m. Overall, the quarter was clearly above our (and the market's) expectations and we expect a strong positive share reaction.

Länk till analysen i sin helhet: https://www.redeye.se/research/1166611/oncopeptides-q1-initial-take-return-to-30-q-q-growth-in-this-quarter?utm_source=finwire&utm_medium=RSS